IDELVION® - Key Publications | CSL Behring Medical Affairs

Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Product Information	Educational Materials	Conferences and Events	Key Publications

Hemophilia B Publications

Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B

^{Tap Image to view Graphical Abstract}

R. Lemons et al. Thieme 2024
Request | Ask a Question | View Article

Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial

G. Kenet, Chambost H.. J. Thrombosis and Hemostasis, 2016
Request | Ask a Question | View Article

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

E. Santagostino, U. Martinowitz, et al. Blood, April 2016
Request | Ask a Question | View Article

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Negrier et al. Haemophilia 2016
Request | Ask a Question | View Article

Hemophilia B Posters

Factor consumption and bleeding outcomes of three commonly used factor IX products for hemophilia B prophylaxis in patients of any age: a retrospective medical chart analysis in the United States

View Poster

Please see full prescribing information for IDELVION

Factor consumption and bleeding outcomes before and after switching to rIX-FP prophylaxis from other factor IX products for hemophilia B: a retrospective medical chart analysis in the United States

View Poster

Please see full prescribing information for IDELVION

Real-World Use of Recombinant Factor IX Fusion Protein in Previously Untreated Patients with Congenital Hemophilia B from the ATHN 8 Study

View Poster

Please see full prescribing information for IDELVION